

Curriculum scientifico di Carmine G. Fanelli

Dati Biografici

Carmine G. Fanelli è nato a Riccia (CB) - 11 Marzo 1959.

Ha conseguito il diploma di maturità presso il Liceo Scientifico "Galileo Galilei" di Riccia nel 1978.

Si è laureato in Medicina e Chirurgia presso l'Università degli Studi di Perugia nel 1987.

Ha conseguito il diploma di specializzazione in Endocrinologia e Malattie del Ricambio presso l'Università degli Studi di Perugia nel 1992.

Ha conseguito il diploma di Dottorato di Ricerca in Fisiopatologia Applicata (IX Ciclo) presso l'Università degli Studi di Firenze/Perugia nel 1997.

Dal 1998 al 2007 è stato ricercatore a contratto presso il Dipartimento di Medicina, Sezione di Scienze Endocrine e Metaboliche dell'Università degli Studi di Perugia

Dal 2007 al 30/11/2017 è stato Ricercatore Confermato in Endocrinologia e Metabolismo (Settore Scientifico Disciplinare MED/13) presso il Dipartimento di Medicina, Sezione di Scienze Endocrine e Metaboliche dell'Università degli Studi di Perugia - Azienda Ospedaliera di Perugia.

Dal 01/12/2017 ad oggi è Professore Associato in Endocrinologia (Settore Scientifico Disciplinare MED/13) presso il Dipartimento di Medicina, Sezione di Endocrinologia e Malattie del Metabolismo.

Attività di ricerca

Carmine G. Fanelli ha iniziato la sua attività di ricerca nel settore delle malattie metaboliche e relative complicanze nel 1988.

Ha pubblicato articoli in extenso su riviste con "peer review" (impact factor totale > 900; impact factor medio > 8,0) ed è stato relatore ai più importanti congressi nazionali ed internazionali del settore. I lavori hanno ricevuto 5908 citazioni con H-index di 39 (Banca Dati WOS).

Esperienze internazionali

Esperienza professionale in qualità di "Research Fellow" presso la Divisione di endocrinologia della Washington University School of Medicine in St. Louis, USA, dal 1994 al 1997.

Nel 1997 ha ottenuto la ECFMG Certification rilasciata dall'Educational Commission for Foreign Medical Graduates (<http://www.ecfm.org>), previo superamento dello Step I (Basic Sciences), dello Step II CK (Clinical Knowledge Component) e dello Step II CS (Clinical Skills Examination) dell'esame di abilitazione USMLE (United States Medical Licensing Examination, <http://www.usmle.org>).

Carmine G. Fanelli è collaboratore del progetto RISC (Relationship between Insulin Sensitivity and

Cardiovascular Disease Risk) per conto del “European Group for the study of Insulin Resistance (EGIR). Il coordinatore responsabile del progetto è il Prof. E. Ferrannini, Professore di Medicina Interna, Pisa.

Attività didattica:

ENDOCRINOLOGIA, Attività didattica: Titolarità (Docente responsabile dell'insegnamento); Corso: SCIENZE DELLA ALIMENTAZIONE E DELLA NUTRIZIONE UMANA (Laurea Magistrale - LM17 - PERUGIA).

ENDOCRINOLOGIA E MALATTIE DEL METABOLISMO - MOD. 1, Attività didattica: Titolarità Insegnamento: PATOLOGIA SISTEMICA I (Docente responsabile dell'insegnamento); Corso: MEDICINA E CHIRURGIA (Laurea Magistrale Ciclo Unico 6 anni - MU01 - PERUGIA).

ENDOCRINOLOGIA E SCIENZE DELL'ALIMENTAZIONE E DEL BENESSERE, Attività didattica: Titolarità (Docente responsabile dell'insegnamento); Corso: SCIENZE E TECNICHE DELLO SPORT E DELLE ATTIVITÀ MOTORIE PREVENTIVE E ADATTATE (Laurea Magistrale - LM92 - PERUGIA).

TIROCINIO PROFESSIONALIZZANTE IN ENDOCRINOLOGIA E MALATTIE DEL METABOLISMO; Attività didattica: Titolarità Insegnamento: PATOLOGIA SISTEMICA I (Docente responsabile dell'insegnamento); Corso: MEDICINA E CHIRURGIA (Laurea Magistrale Ciclo Unico 6 anni - MU01 - PERUGIA)

Partecipa in qualità di tutor all'attività didattica della Scuola di Specializzazione in Endocrinologia e Nefrologia dell'Università di Perugia.

Premi e riconoscimenti

Carmine G. Fanelli ha ricevuto nel 1998 il premio Ely Lilly/EASD Research Fellowship in Diabetes and Metabolism.

E' revisore per le più importanti riviste con peer review nel settore endocrino - metabolico.

E' stato membro del Comitato Scientifico della Società Italiana di Diabetologia nel biennio 2010-2012.

E' stato Presidente della Sezione Regionale dell'Umbria della Società Italiana di Diabetologia (SID) nel biennio 2010-2012.

E' stato membro del Comitato di Redazione della rivista “Il Diabete” organo ufficiale della Società Italiana di Diabetologia.

Ha partecipato ad attività didattica nell'ambito di interventi di formazione della Società Italiana di Diabetologia (SID).

E' tra gli Autori che hanno redatto gli Standard di Cura del Diabete AMD-SID 2018.

Interessi scientifici: Diabetologia, Endocrinologia e Metabolismo.

PUBBLICAZIONI SCIENTIFICHE

Articoli originali

1. Bonadonna RC, Giaccari A, Buzzetti R, Aimaretti G, Cucinotta D, Avogaro A, Perseghin G, Larosa M, Bolli GB, **Fanelli CG**. Italian Titration Approaches Study (ITAS) in insulin-naïve type 2 diabetes patients: design and population. Nutr Metab Cardiovasc Dis.; DOI: <https://doi.org/10.1016/j.numecd.2019.01.011>; Publication stage: In Press Accepted Manuscript; Published online: February 8, 2019
2. Owens DR, Bailey TS, **Fanelli C**, Yale J-F, Bolli GB. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation. Diabetes Metab. 2018; doi: 10.1016/j.diabet.2018.11.004. [Epub ahead of print] Review
3. Lucidi P, Porcellati F, Bolli GB, **Fanelli CG**. Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia. Ann Transl Med 2018. doi: 10.21037/atm.2018.11.23
4. Nicolucci A, Prosperini G, Buzzetti R, De Cosmo S, **Fanelli CG**, Napoli R, Giorgino F; AGERE Study Group. A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes. Minerva Endocrinol. 2018;43:501-510.
5. Porcellati F, Lucidi P, Candeloro P, Cioli P, Marinelli Andreoli A, Curti G, Bolli GB, **Fanelli CG**. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes. Diabetes Care. 2018 Oct 10. pii: dc180706. doi: 10.2337/dc18-0706
6. Lucidi P, Porcellati F, Bolli GB, **Fanelli CG**. Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology. Curr Diab Rep. 2018;18(10):83. doi: 10.1007/s11892-018-1065-6
7. Moscardó V, Bondia J, Ampudia-Blasco FJ, **Fanelli CG**, Lucidi P, Rossetti P. Plasma Insulin Levels and Hypoglycemia Affect Subcutaneous Interstitial Glucose Concentration. Diabetes Technol Ther. 2018 Apr;20(4):263-273. doi: 10.1089/dia.2017.0219
8. Lucidi P, Porcellati F, Marinelli Andreoli A, Candeloro P, Cioli P, Bolli GB, **Fanelli CG**. Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. Diabetes Metab. 2018;44(4):368-372. doi: 10.1016/j.diabet.2017.05.004
9. Ranucci C, Pippi R, Buratta L, Aiello C, Gianfredi V, Piana N, Reginato E, Tirimagni A, Chiodini E, Sbroma Tomaro E, Gili A, De Feo P, **Fanelli C**, Mazzeschi C. Effects of an

Intensive Lifestyle Intervention to Treat Overweight/Obese Children and Adolescents. Biomed Res Int. 2017;2017:8573725. doi: 10.1155/2017/8573725

10. Sbroma Tomaro E, Pippi R, Reginato E, Aiello C, Buratta L, Mazzeschi C, Perrone C, Ranucci C, Tirimagni A, Russo A, Fatone C, **Fanelli C**, De Feo P. Intensive lifestyle intervention is particularly advantageous in poorly controlled type 2 diabetes. Nutr Metab Cardiovasc Dis. 2017;27(8):688-694. doi: 10.1016/j.numecd.2017.06.009
11. Porcellati F, Lin J, Lucidi P, Bolli GB, **Fanelli CG**. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials. Medicine (Baltimore). 2017;96(5):e6022. doi: 10.1097/MD.0000000000006022.
12. Porcellati F, Lucidi P, Bolli GB, **Fanelli CG**. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes Metab. 2015;41(6 Suppl 1):6S16-6S20. doi: 10.1016/S1262-3636(16)30004-0.
13. Porcellati F, Lucidi P, Bolli GB, **Fanelli CG**. How to accurately establish pharmacokinetics/dynamics of long-acting insulins in humans: relevance to biosimilar insulins. Diabetes Care. 2015;38:2237-40. doi: 10.2337/dc15-1848
14. Lucidi P, Porcellati F, Marinelli Andreoli A, Carriero I, Cioli P, Candeloro P, Bolli GB, **Fanelli CG**. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes Mellitus: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Diabetes Care 2015;38:1–7 | DOI: 10.2337/dc15-0801
15. Lucidi P, Porcellati F, Yki-Järvinen H, Riddle MC, Candeloro P, Marinelli Andreoli A, Bolli GB, **Fanelli CG**. Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. Diabetes care. 38(7):e96-e97, 2015
16. Porcellati F, Lucidi P, Rossetti P, Cioli P, Candeloro P, Andreoli AM, Marzotti S, Ambrogi M, Bolli GB, **Fanelli CG**. Pharmacokinetics and pharmacodynamics of insulin glargine given evening as compared to morning in type 2 diabetes mellitus. Diabetes Care. 2015, 38(3): 503-512
17. Lucidi P, Porcellati F, Candeloro P, Cioli P, Marinelli Andreoli A, Marzotti S, Schmidt R, Bolli GB., **Fanelli CG**. Glargine metabolism over 24 hours following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study. Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):709-16. doi: 10.1016/j.numecd.2014.02.008. Epub 2014 Feb 22.

18. Porcellati F, Lucidi P, Bolli GB, **Fanelli CG**. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care. 2013 Dec;36(12):3860-2. doi: 10.2337/dc13-2088.
19. Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P, Hahn A, Schmidt R, Bolli GB, **Fanelli CG**. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care. 2012 Dec;35(12):2647-9. doi: 10.2337/dc12-0271. Epub 2012 Oct 18.
20. Porcellati F, Lucidi P, Rossetti P, Candeloro P, Marinelli Andreoli A, Marzotti S, Cioli P, Bolli GB, **Fanelli CG**. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine and detemir in type 2 diabetes mellitus. Diabetes Care 2011 Dec;34(12):2521-3. Epub 2011 Oct 4.
21. Porcellati F, Bolli GB, **Fanelli CG**. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther. 13 Suppl 1:S15-24, 2011 Jun
22. Bolli GB, Lucidi P, Porcellati F, **Fanelli CG**. Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes. Diabetes Care May 2011 34:S220-S224; doi:10.2337/dc11-s224
23. Lucidi P, Porcellati F, Rossetti P, Candeloro P, Cioli P, Marzotti S, Andreoli AM, Fede R, Bolli GB, **Fanelli CG**. [Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetes: A randomized cross-over study](#). Diabetes Care. 2011 Apr 15. [Epub ahead of print]
24. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. Lucidi P, Rossetti P, Porcellati F, Pampanelli S, Candeloro P, Andreoli AM, Perriello G, Bolli GB, **Fanelli CG**. Diabetes. 2010 Jun;59(6):1349-57. Epub 2010 Mar 18.
25. Rossetti P, Bondia J, Vehí J, **Fanelli CG**. Estimating plasma glucose from interstitial glucose: the issue of calibration algorithms in commercial continuous glucose monitoring devices. Sensors (Basel). 2010;10(12):10936-52. doi: 10.3390/s101210936.
26. Porcellati F, Rossetti P, Candeloro P, Lucidi P, Cioli P, Andreoli AM, Ghigo E, Bolli GB, **Fanelli CG**. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. J Clin Endocrinol Metab. 2009 Aug;94(8):3017-24. Epub 2009 May 26.

27. Rossetti P, Porcellati F, Lucidi P, Ricci NB, Candeloro P, Cioli P, Santeusanio F, Bolli GB, **Fanelli CG**. Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. Diabetes. 58:194-202, 2009 Jan. Epub 2008 Oct 13.
28. Rossetti P, Porcellati F, **Fanelli CG**, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch. Physiol. Biochem. 114:3-10, 2008 Feb
29. Rossetti P, Porcellati F, Busciantella Ricci N, Candeloro P, Cioli P, Nair KS, Santeusanio F, Bolli GB, and **Fanelli CG**. Effect of oral amino acid on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in non-diabetic and type 1 diabetic people. Diabetes 57:1905-17. 2008 Jul. Epub 2008 Apr 4.
30. Porcellati F, Rossetti P, Bolli GB, **Fanelli CG**. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study. Response to Banarar. Diabete Care. 31(3):e17, 2008 Mar.
31. Rossetti P, Porcellati F, Busciantella Ricci N, Candeloro P, Cioli P, Bolli GB, **Fanelli CG**. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes. 57: 746-56, 2008 Mar
32. Rossetti P, Porcellati F, Bolli GB, **Fanelli CG**. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Diabetes Care. 31(Suppl. 2):113-120, 2008 Feb.
33. Porcellati F, Rossetti P, Busciantella Ricci N, Marzotti S, Lucidi P, Luzio S, Owens D, Bolli G.B, **Fanelli CG**. Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care. 30: 2447-52, 2007 Oct. Epub 2007 Jul 10.
34. Porcellati F, Rossetti P, Busciantella Ricci N, Pampanelli S, Torlone E, Hernandez Campos S, Marinelli Andreoli A, Bolli GB, **Fanelli CG**. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after one week of use as compared to its first administration in subjects with type 1 diabetes mellitus. Diabetes Care. 30:1261-1263, 2007 May
35. Porcellati F, Pampanelli F, Rossetti P, Busciantella Ricci N, Marzotti S, Lucidi P, Santeusanio F, Bolli GB, **Fanelli CG**. Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic

euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. Diabetologia. 50(2):422-30, 2007 Feb.

36. **Fanelli CG**, Rossetti P. Counterregulatory responses in CSII. Diabetes Res Clin Pract. 74 Suppl 2:S108-11, 2006 Dec
37. Gambelunghe G, Fatone C, Ranchelli A, **Fanelli C**, Lucidi P, Cavaliere A, Avenia N, d'Ajello M, Santeusanio F, De Feo P. A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. J Endocrinol Invest. 29(9):RC23-6, 2006 Oct
38. Cherubini V, Iannilli A, Iafusco D, Cardella F, Giamprini MS, **Fanelli C**, Coppa GV. Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes. Diabetes Care. 29(10):2311-2312, 2006 Oct.
39. Rossetti P, Porcellati F, **Fanelli CG**, Bolli GB. Evaluation of the Accuracy of a Microdialysis-based Glucose Sensor During Insulin-Induced Hypoglycemia, its Recovery and Post-hypoglycemic Hyperglycemia in Humans. Diabetes Technology & Therapeutics Volume 8:326-337, 2006 June.
40. **Fanelli CG**, Porcellati F, Rossetti P, Bolli GB. Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab Cardiovasc Dis. 16 Suppl 1:S28-34, 2006 Mar.
41. Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Fatone C, Taglioni C, **Fanelli C**, Broglio F, Ghigo E, Bolli GB, Santeusanio F, De Feo P. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis. 15: 410-417, 2005 Dec.
42. Patrì A, Facchiano E, Annetti C, Aisa MC, Galli F, **Fanelli C**, Donini A. Early Improvement of Glucose Tolerance after Ileo-Jejunal Transposition in a Non-obese Type 2 Diabetes Rat Model. Obes Surg. 15: 1258-1264, 2005 Oct.
43. Di Loreto C, **Fanelli C**, Lucidi P, Murdolo G, De Cicco A, Parlanti N, Ranchelli A, Fatone C, Taglioni C, Santeusanio F, De Feo P. Make Your Diabetic Patients Walk: Long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care. 28(6):1295-1302, 2005 June.
44. **Fanelli CG**, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycemia: the size of the problem. Diabet Metab Res Rev. 20 (Suppl 2):S32-S42, 2004 Dec.

45. Porcellati F, Rossetti P, Pampanelli S, **Fanelli CG**, Torlone E, Scionti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared to NPH in patients with type 1 diabetes mellitus given mealtime lispro insulin. Diabetic Med. 21:1213-1220, 2004 Nov.
46. Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Ranchelli A, Fatone C, Taglioni C, **Fanelli C**, Santeusanio F, De Feo P. Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. J Endocrinol Invest. 27(5):12-15, 2004 May
47. Murdolo G, Lucidi P, Di Loreto C, Parlanti N, De Cicco A, Fatone C, **Fanelli CG**, Bolli GB, Santeusanio F, De Feo P. Insulin is required for prandial ghrelin suppression in humans. Diabetes. 52(12):2923-27, 2003 Dec.
48. Porcellati F, Pampanelli S, Rossetti P, Cordoni C, Marzotti S, Scionti L, Bolli GB, **Fanelli CG**. Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans. Diabetes. 52(11):2774-83, 2003 Nov.
49. Rossetti P. Pampanelli S. **Fanelli C**. Porcellati F. Costa E. Torlone E. Scionti L. Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 26(5):1490-6, 2003 May.
50. Murdolo G, Lucidi P, Di Loreto C, Parlanti N, De Cicco A, **Fanelli C**, Perriello G, Mughetti D, Pippi R, Brozzetti A, Santeusanio F, De Feo P. Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement. J Endocrinol Invest. 26(3):244-9, 2003 Mar.
51. Luca G. Calvitti M. Basta G. Baroni T. Neri LM. Becchetti E. Capitani S. Novaes G. Correa-Giannella ML. Kalapothakis E. Engler SS. Eliaschewitz FG. Sogayar MC. **Fanelli C**, Brunetti P. Calafiore R. Mitogenic effects of Brazilian arthropod venom on isolated islet beta cells: in vitro morphologic ultrastructural and functional studies. J Invest Med. 51(2):79-85, 2003 Mar.
52. Di Loreto C. **Fanelli C**. Lucidi P. Murdolo G. De Cicco A. Parlanti N. Santeusanio F. Brunetti P. De Feo P. Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care. 26(2):404-8, 2003 Feb.
53. **Fanelli CG**. Pampanelli S. Porcellati F. Bartocci L. Scionti L. Rossetti P. Bolli GB. Rate of fall of blood glucose and physiological responses of counterregulatory hormones,

- clinical symptoms and cognitive function to hypoglycaemia in Type 1 diabetes mellitus in the postprandial state. Diabetologia. 46:53-64, 2003 Jan.
54. Lucidi P. Murdolo G. Di Loreto C. De Cicco A. Parlanti N. **Fanelli C.** Santeusanio F. Bolli GB. De Feo P. Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. Diabetes. 51(10):2911-4, 2002 Oct.
55. Bolli GB. Pampanelli S. Porcellati F. **Fanelli CG.** Recovery and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus. Diab. Nutr. Metab. 15:402-409, 2002 Oct.
56. **Fanelli CG.** Pampanelli S. Porcellati F. Cognitive function in hypoglycaemia. Diab. Nutr. Metab. 15:367-372, 2002 Oct
57. De Feo P. Pampanelli S. Porcellati F. Rossetti P. **Fanelli CG.** Bolli GB. Adrenaline vs glucagon in the primacy of glucose counterregulation. Diab. Nutr. Metab. 15:323-328, 2002 Oct.
58. **Fanelli CG.** Pampanelli S. Porcellati F. Rossetti P. Brunetti P. Bolli GB. Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann Intern Med. 136 (7):504-14, 2002 Apr.
59. Segel SA. **Fanelli CG.** Dence CS. Markham J. Videen TO. Paramore DS. Powers WJ. Cryer PE. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes. 50:1911-1917, 2001 Aug.
60. Lepore M. Pampanelli S. **Fanelli C.** Porcellati F. Bartocci L. Di Vincenzo A. Cordoni C. Costa E. Brunetti P. Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 49:2142-8, 2000 Dec.
61. Luca G. Calvitti M. Neri LM. Becchetti E. Capitani S. Basta G. Angeletti G. **Fanelli C.** Brunetti P. Calafiore R. Sertoli cell-induced reversal of adult rat pancreatic islet β -cells into fetal-like status: potential implications for islet transplantation in type 1 diabetes mellitus. J Invest Med. 48:441-8, 2000 Nov. (SOLO ABSTRACT SENZA ARTICOLO IN ESTENSO)
62. Bolli GB. **Fanelli CG.** Physiology of glucose counterregulation to hypoglycemia. Endocrinology and Metabolism Clinics of North America. 28:467-493, 1999 Sep.
63. Paramore D. **Fanelli CG.** Shah SD. Cryer PE. Hypoglycemia per se stimulates sympathetic neural as well as adrenomedullary activity, but, unlike the adrenomedullary

response, the forearm sympathetic neural response is not reduced after recent hypoglycemia. Diabetes. 48:1429-1436, 1999, Jul.

64. Dagogo-Jack S. **Fanelli CG**. Cryer PE. Durable reversal of hypoglycemia unawareness in Type 1 diabetes. Diabetes Care. 22(5):866-7, 1999 May.
65. **Fanelli CG**. Paramore DS. Hershey T. Terkamp C. Ovalle F. Craft S. Cryer PE. Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes. 47(12):1920-7, 1998 Dec.
66. Paramore DS. **Fanelli CG**. Shah SD. Cryer PE. Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia. American Journal of Physiology. 275(5 Pt 1):E872-81, 1998 Nov.
67. Ovalle F. **Fanelli CG**. Paramore DS. Hershey T. Craft S. Cryer PE. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes. 47(9):1472-9, 1998 Sep
68. **Fanelli CG**. Dence CS. Markham J. Videen TO. Paramore DS. Cryer PE. Powers WJ. Blood-to-brain glucose transport and cerebral glucose metabolism are not reduced in poorly controlled type 1 diabetes. Diabetes. 47(9):1444-50, 1998 Sep.
69. **Fanelli CG**. Pampanelli S. Porcellati F. Bolli GB. Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. Diabetologia. [Review] [29 refs] 41(6):720-3, 1998 Jun
70. **Fanelli CG**. Bolli GB. Sulphonylureas and pregnancy. Eur J Endocrinol. [Invited Commentary]138(6):615-6, 1998 Jun
71. **Fanelli C**. Pampanelli S. Lalli C. Del Sindaco P. Ciofetta M. Lepore M. Porcellati F. Bottini P. Di Vincenzo A. Brunetti P. Bolli GB. Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on awareness of, and counterregulation to hypoglycemia. Diabetes. 46(7):1172-1181 1997 Jul.
72. Del Sindaco P. Casucci G. Pampanelli S. Polonsky K. **Fanelli C**. Torlone E. Santeusano F. Brunetti P. Bolli GB. Late post-prandial hypoglycaemia as the sole presenting feature of secreting pancreatic beta-cell adenoma in a subtotaly gastrectomized patient. Eur J Endocrinol. 136(1): 96-99 1997 Jan.

73. Hvidberg A. **Fanelli CG**. Hershey T. Terkamp C. Craft S. Cryer PE . Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. Diabetes. 45(8):1030-6, 1996 Aug.
74. Pampanelli S. **Fanelli C**. Lalli C. Ciofetta M. Sindaco PD. Lepore M. Modarelli F. Rambotti AM. Epifano L. Di Vincenzo A. Bartocci L. Annibale B. Brunetti P. Bolli GB . Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia. 39(6):677-86, 1996 Jun.
75. Dagogo-Jack S. **Fanelli C**. Paramore D. Brothers J. Landt M . Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes. 45(5):695-8, 1996 May.
76. Bolli GB. **Fanelli CG** . Unawareness of hypoglycemia [editorial]. New England Journal of Medicine. 333(26):1771-2, 1995 Dec 28.
77. **Fanelli C**. Bassotti G. Giansanti M. Bartoli A. Bolli GB . Posttraumatic ileal stenosis mimicking Crohn's disease. Journal of Clinical Gastroenterology. 20(4):338-40, 1995 Jun.
78. **Fanelli C**. Pampanelli S. Calderone S. Lepore M. Annibale B. Compagnucci P. Brunetti P. Bolli GB . Effects of recent, short-term hyperglycemia on responses to hypoglycemia in humans. Relevance to the pathogenesis of hypoglycemia unawareness and hyperglycemia-induced insulin resistance. Diabetes. 44(5):513-9, 1995 May.
79. **Fanelli C**. Pampanelli S. Epifano L. Rambotti AM. Di Vincenzo A. Modarelli F. Ciofetta M. Lepore M. Annibale B. Torlone E. Perriello G. De Feo P. Santeusano F. Brunetti P. Bolli GB. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM [published erratum appears in Diabetologia 1995 Feb;38(2):254]. Diabetologia. 37(12):1265-76, 1994 Dec.
80. **Fanelli C**. Pampanelli S. Epifano L. Rambotti AM. Ciofetta M. Modarelli F. Di Vincenzo A. Annibale B. Lepore M. Lalli C. Brunetti P. Bolli GB. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia. 37(8):797-807, 1994 Aug.
81. Torlone E. **Fanelli C**. Rambotti AM. Kassi G. Modarelli F Di Vincenzo A. Epifano L. Ciofetta M. Pampanelli S. Brunetti P. Bolli GB. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia. 37(7):713-20, 1994 Jul.

82. Bolli GB. Perriello G. **Fanelli CG**. De Feo P . Nocturnal blood glucose control in type I diabetes mellitus. [Review] [147 refs] Diabetes Care. 16 Suppl 3:71-89, 1993 Dec.
83. **Fanelli C**. Di Vincenzo A. Modarelli F. Lepore M. Ciofetta M. Epifano L. Pampanelli S. Brunetti P. Bolli GB . Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. Diabetologia. 36(11):1191-7, 1993 Nov.
84. **Fanelli C**. Calderone S. Epifano L. De Vincenzo A. Modarelli F. Pampanelli S. Perriello G. De Feo P. Brunetti P. Gerich JE. Bolli PB. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. Journal of Clinical Investigation. 92(4):1617-22, 1993 Oct.
85. **Fanelli CG**. Epifano L. Rambotti AM. Pampanelli S. Di Vincenzo A. Modarelli F. Lepore M. Annibale B. Ciofetta M . Bottini P. Porcellati F. Scionti L. Santeusanio F. Brunetti P. Bolli GB. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 42(11):1683-9, 1993 Nov.
86. Mitrakou A. **Fanelli C**. Veneman T. Perriello G. Calderone S. Platanisiotis D. Rambotti A. Raptis S. Brunetti P. Cryer P. Gerich J. Bolli GB. Reversibility of unawareness of hypoglycemia in patients with insulinomas. New England Journal of Medicine. 329(12):834-9, 1993 Sep 16.
87. Porcellati F. **Fanelli C**. Bottini P. Epifano L. Rambotti AM. Lalli C. Pampanelli S. Scionti L. Santeusanio F. Brunetti P. Hilsted J. Bolli GB. Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. Diabetes. 42(7):1055-64, 1993 Jul.
88. De Feo P. Torlone E. Perriello G. **Fanelli C**. Epifano L. Di Vincenzo A. Modarelli F. Motolese M. Brunetti P. Bolli GB. Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 Diabetes mellitus associated with arterial hypertension. Diabete et Metabolisme. 18(4):283-8, 1992 Jul-Aug. (SOLO ABSTRACT SENZA ARTICOLO IN ESTENSO)
89. Epifano L. Di Vincenzo A. **Fanelli C**. Porcellati F. Perriello G. De Feo P. Motolese M. Brunetti P. Bolli GB. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus. European Journal of Clinical Pharmacology. 43(3):257-63, 1992.

90. **Fanelli CG**. De Feo P. Porcellati F. Perriello G. Torlone E. Santeusanio F. Brunetti P. Bolli GB. Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. Journal of Clinical Investigation. 89(6):2005-13, 1992 Jun.
91. De Feo P. Perriello G. Torlone E. **Fanelli C**. Ventura MM. Santeusanio F. Brunetti P. Gerich JE. Bolli GB. Contribution of adrenergic mechanisms to glucose counterregulation in humans. American Journal of Physiology. 261(6 Pt 1):E725-36, 1991 Dec.
92. Perriello G. De Feo P. Torlone E. **Fanelli C**. Santeusanio F. Brunetti P. Bolli GB. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia. 34(1):21-8, 1991 Jan.
93. De Feo P. Perriello G. Torlone E. **Fanelli C**. Ventura MM. Santeusanio F. Brunetti P. Gerich JE. Bolli GB. Evidence against important catecholamine compensation for absent glucagon counterregulation. American Journal of Physiology. 260(2 Pt 1):E203-12, 1991 Feb.
94. Perriello G. De Feo P. Torlone E. **Fanelli C**. Santeusanio F. Brunetti P. Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia. 33(1):52-9, 1990 Jan.
95. De Feo P. Perriello G. Torlone E. Ventura MM. **Fanelli C**. Santeusanio F. Brunetti P. Gerich JE. Bolli GB. Contribution of cortisol to glucose counterregulation in humans. American Journal of Physiology. 257(1 Pt 1):E35-42, 1989 Jul.
96. De Feo P. Perriello G. De Cosmo S. Ventura MM. Torlone E. **Fanelli C**. Santeusanio F. Bolli GB. Brunetti P. Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. Diabetes, Nutrition & Metabolism. 2:111-8, 1989, Jun.
97. Perriello G. Torlone E. Di Santo S. **Fanelli C**. De Feo P. Santeusanio F. Brunetti P. Bolli GB. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) Diabetes mellitus. Diabetologia. 31(11):811-5, 1988 Nov.
98. De Feo P. Perriello G. Torlone E. Calcinaro F. Basta G. Ventura MM. **Fanelli C**. Di Santo S. Dell'Olio A. Bolli GB. Pathogenesis of fasting hyperglycemia in type 1 diabetes mellitus. Insulin deficiency, Somogyi effect and the dawn phenomenon, a necessary

distinction. [Review] [49 refs] Minerva Endocrinologica. 13(3):151-61, 1988 Jul-Sep. (SOLO RIFERIMENTO da PUBMED)

PUBBLICAZIONI COME COLLABORATORE DEL PROGETTO RISC (Responsabile Prof. E. Ferrannini – Pisa) SU RIVISTE PEER REVIEWED INDICIZZATE

1. Siméon S, Massy Z, Højlund K, Lalic K, Porcellati F, Dekker J, Petrie J, Currie G, Balkau B. Renal function markers and insulin sensitivity after 3 years in a healthy cohort, **the EGIR-RISC study**. *BMC Nephrol*. 2018 May 31;19(1):124. doi: 10.1186/s12882-018-0918-1.
2. Paulmichl K, Hatunic M, Højlund K, Jotic A, Krebs M, Mitrakou A, Porcellati F, Tura A, Bergsten P, Forslund A, Manell H, Widhalm K, Weghuber D, Anderwald CH; Beta-JUDO Investigators; **RISC Investigators**. Modification and Validation of the Triglyceride-to-HDL Cholesterol Ratio as a Surrogate of Insulin Sensitivity in White Juveniles and Adults without Diabetes Mellitus: The Single Point Insulin Sensitivity Estimator (SPISE). *Clin Chem*. 2016 Sep;62(9):1211-9. doi: 10.1373/clinchem.2016.257436.
3. Baldi S, Bonnet F, Laville M, Morgantini C, Monti L, Højlund K, Ferrannini E, Natali A; **RISC Investigators**. Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study. *Diabetes Care*. 2013 Dec;36(12):4125-31. doi: 10.2337/dc13-0682. Epub 2013 Oct 15.
4. Bonnet F, Roussel R, Natali A, Cauchi S, Petrie J, Laville M, Yengo L, Froguel P, Lange C, Lantieri O, Marre M, Balkau B, Ferrannini E; DESIR and **RISC Study Groups**. Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. *Diabetologia*. 2013 Nov;56(11):2414-23. doi: 10.1007/s00125-013-3021-y. Epub 2013 Aug 14.
5. Pataky Z, Golay A, Laville M, Disse E, Mitrakou A, Guidone C, Gabriel R, Bobbioni-Harsch E; **RISC Investigators**. Fasting insulin at baseline influences the number of cardiometabolic risk factors and R-R interval at 3years in a healthy population: the RISC Study. *Diabetes Metab*. 2013 Sep;39(4):330-6. doi: 10.1016/j.diabet.2013.05.008.

6. Petrie JR, Malik MO, Balkau B, Perry CG, Højlund K, Pataky Z, Nolan J, Ferrannini E, Natali A; **RISC Investigators**. Euglycemic clamp insulin sensitivity and longitudinal systolic blood pressure: role of sex. *Hypertension*. 2013 Aug;62(2):404-9. doi: 10.1161/HYPERTENSIONAHA.111.00439. Epub 2013 Jun 3.
7. Kozakova M, Natali A, Dekker J, Beck-Nielsen H, Laakso M, Nilsson P, Balkau B, Ferrannini E; **RISC Investigators**. Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. *Arterioscler Thromb Vasc Biol*. 2013 Jun;33(6):1409-17. doi: 10.1161/ATVBAHA.112.300948. Epub 2013 Apr 18.
8. Bobbioni-Harsch E, Pataky Z, Makoundou V, Laville M, Disse E, Anderwald C, Konrad T, Golay A; **RISC Investigators**. From metabolic normality to cardiometabolic risk factors in subjects with obesity. *Obesity (Silver Spring)*. 2012 Oct;20(10):2063-9. doi: 10.1038/oby.2012.69. Epub 2012 Mar 16.
9. [Kozakova M](#), [Palombo C](#), [Eng MP](#), [Dekker J](#), [Flyvbjerg A](#), [Mitrakou A](#), [Gastaldelli A](#), [Ferrannini E](#); **RISC Investigators**. **Collaborators (142)**. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. *Hepatology*. 2012 May;55(5):1406-15. doi: 10.1002/hep.25555.
10. [Handberg A](#), [Højlund K](#), [Gastaldelli A](#), [Flyvbjerg A](#), [Dekker JM](#), [Petrie J](#), [Piatti P](#), [Beck-Nielsen H](#); **RISC Investigators**. **Collaborators (147)**. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. *J Intern Med*. 2012 Mar;271(3):294-304. doi: 10.1111/j.1365-2796.2011.02442.x. Epub 2011 Sep 14.
11. Rebelos E, Muscelli E, Natali A, Balkau B, Mingrone G, Piatti P, Konrad T, Mari A, Ferrannini E; RISC Study Investigators. **Collaborators (117)**. [Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study](#). *Diabetes*. 2011 Jul;60(7):1938-45. Epub 2011 May 26.
12. Bonnet F, Ducluzeau PH, Gastaldelli A, Laville M, Anderwald CH, Konrad T, Mari A, Balkau B; RISC Study Group. **Collaborators (152)**. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. *Diabetes*. 2011 Jun;60(6):1660-7. Epub 2011 Apr 26.
13. Ferrannini E, Natali A, Muscelli E, Nilsson PM, Golay A, Laakso M, Beck-Nielsen H, Mari A; RISC Investigators. **Collaborators (117)**. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. *Diabetologia*. 2011 Jun;54(6):1507-16. Epub 2011 Mar 22.
14. Vangipurapu J, Stančáková A, Kuulasmaa T, Paananen J, Kuusisto J; EGIR-RISC Study Group, Ferrannini E, Laakso M. **Collaborators (146)**. A novel surrogate index for hepatic insulin resistance. *Diabetologia*. 2011 Mar;54(3):540-3. Epub 2010 Nov 25.

15. Natali A, Muscelli E, Mari A, Balkau B, Walker M, Tura A, Anderwald C, Golay A, Ferrannini E; Relationship between Insulin Sensitivity and Cardiovascular disease investigators. **Collaborators (136)**. Insulin sensitivity and beta-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance. J Clin Endocrinol Metab. 2010 Oct;95(10):4703-11. Epub 2010 Jul 21.
16. Anderwald C, Stadler M, Golay A, Krebs M, Petrie J, Luger A; **RISC Investigators**. Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults. Heart. 2010 Aug;96(15):1191-200.
17. Kozàková M, Palombo C, Morizzo C, Nolan JJ, Konrad T, Balkau B; **RISC Investigators**. Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population. Eur Heart J. 2010 Jun;31(12):1511-9.
18. de Rooij SR, Dekker JM, Kozakova M, Mitrakou A, Melander O, Gabriel R, Guidone C, Højlund K, Murphy MS, Nijpels G; RISC Group Investigators. Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: **the RISC study**. Eur J Endocrinol. 2009 Aug;161(2):223-30.
19. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B; **RISC Investigators**. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009 May;49(5):1537-44.
20. Muscelli E, Kozàková M, Flyvbjerg A, Kyriakopoulou K, Astiarraga BD, Glintborg D, Konrad T, Favuzzi A, Petrie J; RISC investigators. The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. Am J Hypertens. 2009 Apr;22(4):364-70. doi: 10.1038/ajh.2009.16. Epub 2009 Feb 12.
21. Kozakova M, Palombo C, Paterni M, Anderwald CH, Konrad T, Colgan MP, Flyvbjerg A, Dekker J. Body composition and common carotid artery remodeling in a healthy population. Relationship between Insulin Sensitivity Cardiovascular risk **Investigators**. J Clin Endocrinol Metab. 2008 Sep;93(9):3325-32.
22. Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, Lalic N, Walker M; European Group for the Study of Insulin Resistance Relationship Between Insulin Sensitivity and Cardiovascular Disease Risk Study Group (**Collaborators 123**). Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care. 2008 31(4):789-94, Apr. Epub 2008 Jan 30.
23. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E; Report prepared on behalf of the EGIR-RISC Study Group. **The EGIR-RISC STUDY** (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia. 2004 Mar;47(3):566-570. doi: 10.1007/s00125-004-1335-5. Epub 2004 Feb 14.

PUBBLICAZIONI COME COLLABORATORE DELLO STUDIO: BEGIN BB T2D

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. [Lancet](#). 2012 Apr 21;379(9825):1498-507.

CAPITOLI DI LIBRI INTERNAZIONALI

1. Fanelli C.G., Lucidi P., Bolli G.B., Porcellati F. (2018) Hypoglycemia. In: Bonora E., DeFronzo R. (eds) Diabetes Complications, Comorbidities and Related Disorders. Endocrinology. Springer, Cham, 1-38. DOI https://doi.org/10.1007/978-3-319-27316-7_22-1.
2. Bolli GB, Porcellati F, Lucidi P, **Fanelli CG**. Glucose Control in Diabetes: Targets And Therapy. In "Technological advancements in the Treatment of type 1 diabetes". Bruttomesso D, Grassi G (eds): Front Diabetes. Basel, Karger, 2015, vol 24, pp 1-10 (DOI:10.1159/000363460)
3. **Fanelli CG**. Porcellati F. Pampanelli S. Bolli GB. Recognition, treatment and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus. In: "Diabetes: from Research to Diagnosis & Treatment". Ed. Itmar Raz, Jay S. Skyler, Eleazar Shafir. Martin Dunitz Publisher, London. pp. 363-78, 2003 Jan.
4. Bolli GB. **Fanelli CG**. Porcellati F. Pampanelli S. Responses to hypoglycemia. In: "Textbook of Diabetic Neuropathy". Ed. Arnold F. Gries, Phillip A. Low, Norman E. Cameron, Dan Ziegler. Thieme Publishing Group, Stuttgart. pp. 286-94, 2003 Jan.
5. Bolli GB. De Feo P. Perriello G. Torlone E. **Fanelli C**. Epifano L. Di Vincenzo A. Rambotti A. Lalli C. Glucose counterregulation and insulin action in hypoglycaemia. In: Recent advances on hypoglycemia. Editors: Andreani D. Lefebvre PJ. Marks V. Tamburrano G. Raven Press. 89:31-47, 1992
6. Brunetti P. **Fanelli C**. Bolli GB. Glycaemic thresholds in normal humans, in patients with insulinoma and type I diabetes mellitus. In: Recent advances on hypoglycemia. Editors: Andreani D. Lefebvre PJ. Marks V. Tamburrano G. Raven Press. 89:219-227, 1992
7. Bolli GB. De Feo P. Perriello G. Torlone E. **Fanelli C**. Santeusanio F. Brunetti P. Substrate production and utilization during insulin-induced hypoglycaemia. In: Diabetes, Obesity and hyperlipidemias-IV. Crepaldi G. Tiengo A and Enzi G, editors. Elsevier Science Publisher. 297-309, 1990
8. De Feo P. Perriello G. Torlone E. **Fanelli C**. Santeusanio F. Brunetti P. Bolli GB. Sustained effects of glucagon on increased hepatic glucose production during counterregulation in man. In: Diabetes, Obesity and hyperlipidemias-IV. Crepaldi G. Tiengo A and Enzi G, editors. Elsevier Science Publisher. 311-315, 1990

PUBBLICAZIONI E CAPITOLI DI LIBRI E GIORNALI NAZIONALI

1. Lucidi P, Porcellati F, Pascucci C, Cardini F, Marinelli Andreoli A, Bolli GB, **Fanelli CG**. L'ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla. Il Diabete 2018; vol. 30 - N. 2, 95-106. DOI: 10.30682/ildia1802a
2. Ranucci C, Finali M, Chiodini E, Reginato E, Pippi R, Aiello C, Tirimagni A, Piana N, Buratta L, Solinas A, De Feo P, **Fanelli C**. Metti in moto la terza età: un progetto pilota per un invecchiamento attivo e in buona salute. Systema Salute. La rivista italiana di educazione sanitaria e promozione della salute. 62, 2 2018: pp. 283-295
3. Porcellati F, Lucidi P, Marinelli Andreoli A, Bolli GB, **Fanelli CG**. Ipoglicemia: fisiopatologia e clinica. Il Diabete 2017; Vol. 29, N. 4, 378-399.
4. Francesca Porcellati, **Carmine G. Fanelli**, Geremia B. Bolli. Gli Analoghi dell'Insulina ad Azione Ritardo: dalla storia di ieri alle opzioni di oggi. MEDIA 17:34-49, 2017
5. Insulina Biosimilare: è uguale al farmaco originator? Porcellati F, Bolli GB, **Fanelli CG**. Il Diabete 2016; Vol. 28, N 1, 52-59.
6. Porcellati F, Bolli GB, **Fanelli CG**. Ipoglicemia: implicazioni cliniche e impatto sulla salute. G It Diabetol Metab 2015; 35:196-204
7. Marinelli Andreoli A, Chiovoloni M, Lucidi P, Porcellati F, Ruffini F, Capruzzi M, Carriero I, Bolli GB, **Fanelli CG**. Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari. G It Diabetol Metab. 2015; 35:130-135
8. Giorgino F, Baroni M, Boemi M, Bonadonna R, Broglio F, Consoli A, Di Cianni G, Esposito K, **Fanelli C**, Gentile S, Giordano C, Marchesini G, Pozzilli P, Sesti G, Squatrito S, Trevisan R, Vettor R. Gli agonisti del recettore del GLP-1 nella terapia del diabete di tipo 2. Focus sulla terapia di combinazione con insulina basale. Il Diabete Vol. 26, 2:65-80, 2014
9. **Fanelli C**. Indagine sull'atteggiamento del diabetologo nei confronti dell'ipoglicemia nel paziente con diabete. Commento. Il Diabete Vol. 26, 1:22-24, 2014
10. Del Prato S, Fanelli C, Giaccari A, Mannucci E, Sciacca L, Torri V, a nome della Società Italiana di Diabetologia. Diabete e Cancro. Il Diabete Vol. 23, 2:82-95, 2011
<http://www.ildiabeteonline.it/giornale.html>

11. Del Prato S, Sesti G, Bonadonna RC, Consoli A, Dotta F, **Fanelli CG**, Mannucci E, Miccoli R, Pontiroli AE, Pozzilli P, Vespasiani G, Vigneri R. La terapia insulinica nel diabete mellito tipo 2. Rassegna. Il Diabete Vol. 23, 1:36-54, 2011
<http://www.ildiabeteonline.it/giornale.html>

12. **Fanelli CG.**, Bolli GB. Malattie della midollare del surrene. In: Malattie delle Ghiandole Endocrine, del Metabolismo e della Nutrizione. Trattato di Medicina Interna Fondato da Paolo Larizza. 14 Tomi. Piccin Editore, Padova. ISBN: 242-0-1209514-0-8, www.piccin.it, 321-346, 2011

13. **Fanelli CG.**, Bolli GB. Disordini ipoglicemici. In: Malattie delle Ghiandole Endocrine, del Metabolismo e della Nutrizione. Trattato di Medicina Interna Fondato da Paolo Larizza. 14 Tomi. Piccin Editore, Padova. ISBN: 242-0-1209514-0-8, www.piccin.it, 847-872, 2011

14. Perriello G, **Fanelli CG**. Prevenzione dell'ipoglicemia nel paziente diabetico. MeDia 7:10-16, 2007

15. **Fanelli CG**. Ipoglicemia: cause e prevenzione. La terapia insulinica. PRIMULA MULTIMEDIA S.r.L. Edizione. Pisa. pp.308-322, 2007

16. **Fanelli C**. Marcature strette. Ricerca Roche – Diabete. Editore CE.D.RI.M. Vol 23:24-25, Marzo 1999

17. **Fanelli C**. Ipoglicemia. Giornale Italiano di Diabetologia. “L'educazione terapeutica del paziente diabetico: attualità e prospettive”. Supplemento Vol. 19, 2:101-105, 1998

18. **Fanelli C**. Ipoglicemia nel diabete mellito. Il Diabete – “Complicanze acute del diabete”. Vol. 9, 2:93-98, 1997

19. **Fanelli CG**. Ipoglicemia Asintomatica. Diabetes versus Diabetes – “Controllo Metabolico e Complicanze Diabetiche”. Vol .2, 2:66-69, 1995

20. Bolli GB. **Fanelli C**. Acidi grassi liberi e diabete mellito di tipo I. Il Diabete. Vol. 4, 3:233-240, 1992

21. Bolli GB. **Fanelli C**. Pampanelli S. La terapia insulinica del diabete mellito. Ligand Quarterly. Vol.11, 3:357-362, 1992

22. **Fanelli C.** Rambotti AM. Calderone S. Epifano L. Di Vincenzo A. Porcellati F. Torlone E. Modarelli F. De Feo P. Perriello G. Bolli GB. Reversibilità della sindrome della perdita dei sintomi all'ipoglicemia (*Hypoglycemia unawareness*) dopo asportazione chirurgica di un insulinoma: una lezione importante per la terapia insulinica intensiva del diabete mellito di tipo 1. Giornale Italiano di Diabetologia. Vol. 12:269-76, 1992
23. **Fanelli C.** Perriello G. Misericordia P. Volpi E. Moriconi V. Ventura MM. Santeusanio F. Bolli GB. Effetti dell'iperglicemia e dell'iperinsulinemia sull'insulino-resistenza epatica e muscolare del diabete mellito di tipo 2 (NIDDM) associato o non all'obesità. Il Diabete. Vol 4 (Suppl. 1):140-144, 1992
24. Porcellati F. **Fanelli C.** Rambotti AM. Bottini P. Epifano L. Scionti L. Bolli GB. Brunetti P. Meccanismi dell'ipotensione arteriosa dopo iniezione di una dose terapeutica sottocutanea di insulina nel diabete mellito complicato da neuropatia autonoma. Il Diabete. Vol 4 (Suppl. 1):595-598, 1992
25. **Fanelli C.** Porcellati F. Bolli GB. Perdita dei sintomi dell'ipoglicemia: un rischio insidioso della terapia insulinica intensiva. Rassegna. Il Diabete. Vol. 3, 2:80-102, 1991
26. Perriello G. Torlone E. **Fanelli C.** Epifano L. Rambotti AM. Volpi E. Di Vincenzo A, Santeusanio F. Bolli GB. La secrezione notturna di ormone della crescita è causa del fenomeno dell'alba nel diabete mellito di tipo 1. In: Parma Diabete '90. Università degli Studi di Parma, editor. 81-89, 1990

99.